Vertex Pharmaceuticals traded at $507.23 this Wednesday July 8th, decreasing $15.02 or 2.88 percent since the previous trading session. Looking back, over the last four weeks, Vertex Pharmaceuticals lost 13.79 percent. Over the last 12 months, its price rose by 5.90 percent. Looking ahead, we forecast Vertex Pharmaceuticals to be priced at 517.00 by the end of this quarter and at 485.26 in one year, according to Trading Economics global macro models projections and analysts expectations.
Vertex Pharmaceuticals Incorporated is a biotechnology company. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. It offers its products to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. Its CFTR correctors, such as lumacaftor, tezacaftor, and elexacaftor, help CFTR proteins reach the cell surface. It offers pipeline of small molecule medicines in other serious diseases where it has insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.